U.S. Physical Therapy, Inc. USPH
84.84
1.08
1.29%
as of 25 Sep
- Market cap
- $1.3B
- P/E
- 499×
Follow USPH
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
404.00 | 149.92 | 54.99 | 35.69 |
+8 more quarters Free account |
P/S ratio |
1.27 | 1.43 | 1.52 | 1.70 | |
P/FCF ratio |
16.15 | 17.05 | 19.43 | 22.70 | |
P/Operating CF |
30.11 | 298.56 | 47.53 | 64.77 | |
P/B ratio |
2.30 | 2.42 | 2.48 | 2.56 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.51 | 1.64 | 1.67 | 1.86 | |
EV/EBITDA |
12.34 | 12.71 | 11.89 | 12.45 | |
EV/Operating CF |
14.76 | 15.59 | 17.35 | 20.31 | |
EV/FCF |
19.13 | 19.54 | 21.35 | 24.81 | |
Quick Ratio |
1.12 | 1.07 | 0.89 | 1.06 | |
Current Ratio |
1.27 | 1.19 | 1.01 | 1.20 | |
Net Debt/EBITDA |
6.81 | 8.91 | 5.44 | 3.85 | |
Debt/Assets |
17.25% | 15.62% | 12.67% | 12.66% | |
Debt/Equity |
0.48 | 0.41 | 0.32 | 0.30 | |
Asset Turnover |
0.67 | 0.66 | 0.66 | 0.68 | |
Operating CF/Net income |
9.03 | (2.07) | 4.48 | 1.52 | |
Capex/Depreciation |
(0.89) | (0.88) | (0.83) | (0.73) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
8.88% | 9.22% | 8.94% | 8.83% | |
Intangible Assets out of Total Assets |
0.72 | 0.72 | 0.72 | 0.72 | |
Share Based Compensation of Revenue |
1.48% | 1.16% | 1.05% | 1.15% | |
Graham Net Nets |
(0.64) | (0.56) | (0.50) | (0.43) | |
Graham Number |
10.68 | 18.66 | 31.69 | 42.17 | |
Earnings Yield |
0.25% | 0.67% | 1.82% | 2.80% | |
Free Cash Flow Yield |
6.19% | 5.86% | 5.15% | 4.41% | |
Revenue per Share |
14.20 | 13.07 | 13.36 | 12.97 | |
Operating CF per Share |
2.28 | 0.25 | 1.64 | 1.31 | |
Capex per Share |
(0.36) | (0.35) | (0.26) | (0.28) | |
Free Cash Flow per Share |
1.92 | (0.10) | 1.38 | 1.03 | |
Cash per Share |
1.65 | 1.88 | 2.34 | 2.05 | |
Shareholders Equity per Share |
29.81 | 30.95 | 31.43 | 33.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
29.81 | 30.95 | 31.43 | 33.20 | |
Free Cash Flow |
29.01 | (1.56) | 21.01 | 15.63 | |
Working Capital |
29.77 | 21.81 | 0.95 | 23.36 | |
Capital Expenditures |
(5.36) | (5.37) | (3.93) | (4.31) | |
Net Current Asset Value |
(660.03) | (633.51) | (587.13) | (553.05) | |
EV/EBIT |
16.02 | 16.38 | 15.02 | 15.76 | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 | |
Net Profit Margin |
1.78% | (0.93%) | 2.75% | 6.66% | |
Price to Operating Income |
13.53 | 14.30 | 13.67 | 14.42 | |
| Other line items | |||||
Average Receivables |
95.77 | 93.81 | 87.00 | 84.19 | |
Average Payables |
5.56 | 6.42 | 6.00 | 6.89 | |
Average Assets |
1,214.24 | 1,210.87 | 1,185.74 | 1,112.73 | |
Average Common Equity |
475.73 | 484.20 | 483.45 | 494.45 |
Columns are period end dates